CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Reparixindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01220856
NCT01220856Phase 2Completed
CompareCT.gov

A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus

Dompé Farmaceutici S.p.A·interventional·Posted Oct 14, 2010·Updated Mar 11, 2021

In Brief

A Phase 2 clinical trial evaluating Reparixin for Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus. Completed, enrolled 9 participants across 2 sites in 2 countries.

Detailed Summary

Inhibition of CXCL8 activity might represent a relevant therapeutic target to prevent injury occurring after pancreatic islet transplantation. Reparixin is a novel and specific inhibitor of CXCL8. This study is designed to explore the efficacy of reparixin in preventing graft dysfunction after islet transplantation in type 1 diabetes patients (T1D).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Islet Transplantation in Type 1 Diabetes Mellitus
CountriesGermany, Italy
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 14, 2010
Enrollment StartJul 28, 2010
Primary CompletionApr 30, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.7 years ago

Interventions

Reparixindrug

Reparixin + immunosuppression